Neuromuscular Disorders
Volume 19, Issue 12 , Pages 867-873 , December 2009

3rd Annual Dysferlin Conference 2–5 June 2009, Boston, Massachusetts, USA

Received 23 July 2009

References 

  1. Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998;20(1):31–36
  2. Bashir R, Britton S, Strachan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet. 1998;20(1):37–42
  3. Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423(6936):168–172
  4. Lennon NJ, Kho A, Bacskai BJ, Perlmutter SL, Hyman BT, Brown RH. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem. 2003;278(50):50466–50473
  5. Lovering RM, Roche JA, Bloch RJ, DeDeyne PG. Recovery of function in skeletal muscle following 2 different contraction-induced injuries. Arch Phys Med Rehabil. 2007;88(5):617–625
  6. Roche JA, Lovering RM, Bloch RJ. Impaired recovery of dysferlin-null skeletal muscle after contraction-induced injury in vivo. Neuroreport. 2008;19(16):1579–1584
  7. Millay DP, Sargent MA, Osinska H, et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med. 2008;14(4):442–447
  8. Argon Y, Ward S. Caenorhabditis elegans fertilization-defective mutants with abnormal sperm. Genetics. 1980;96(2):413–433
  9. Achanzar WE, Ward S. A nematode gene required for sperm vesicle fusion. J Cell Sci. 1997;110(9):1073–1081
  10. Therrien C, Di Fulvio S, Pickles S, Sinnreich M. Characterization of lipid binding specificities of dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry. 2009;48(11):2377–2384
  11. Sinnreich M, Therrien C, Karpati G. Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology. 2006;66(7):1114–1116
  12. Patel P, Harris R, Geddes SM, et al. Solution structure of the inner DysF domain of myoferlin and implications for limb girdle muscular dystrophy type 2b. J Mol Biol. 2008;379(5):981–990
  13. Cai C, Weisleder N, Ko JK, et al. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem. 2009;284(23):15894–15902
  14. Cai C, Masumiya H, Weisleder N, et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 2009;11(1):56–64
  15. Idone V, Tam C, Goss JW, Toomre D, Pypaert M, Andrews NW. Repair of injured plasma membrane by rapid Ca2+-dependent endocytosis. J Cell Biol. 2008;180(5):905–914
  16. Davis DB, Delmonte AJ, Ly CT, McNally EM. Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum Mol Genet. 2000;9(2):217–226
  17. Doherty KR, Cave A, Davis DB, et al. Normal myoblast fusion requires myoferlin. Development. 2005;132(24):5565–5575
  18. Doherty KR, Demonbreun AR, Wallace GQ, et al. The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J Biol Chem. 2008;283(29):20252–20260
  19. Di Donna S, Mamchaoui K, Cooper RN, et al. Telomerase can extend the proliferative capacity of human myoblasts, but does not lead to their immortalization. Mol Cancer Res. 2003;1(9):643–653
  20. Zhu CH, Mouly V, Cooper RN, et al. Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell. 2007;6(4):515–523
  21. Nishijo K, Hosoyama T, Bjornson CRR, et al. Biomarker system for studying muscle, stem cells and cancer in vivo. FASEB J. 2009;23(8):2681–2690
  22. Brack AS, Conboy MJ, Lee M, et al. Increased Wnt signaling during aging alters myogenic stem cell fate and increases fibrosis. Science. 2007;317:807–810
  23. Sherwood RI, Christensen JL, Conboy IM, et al. Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell. 2004;119:543–554
  24. Cerletti M, Jurga S, Witczak CA, et al. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell. 2008;134:37–47
  25. Vieira NM, Zucconi E, Brandalise V, et al. Human multipotent adipose derived stem cells restore dystrophin expression of Duchenne skeletal muscle cells in vitro. Biol Cell. 2008;100(4):231–241
  26. Vieira NM, Bueno Junior CR, Brandalise V, et al. Sjl dystrophic mice express large amount of human muscle proteins following systemic delivery of human adipose-derived stem cells without immunosuppression. Stem cells. 2008;26(9):2391–2398
  27. Skuk D, Roy B, Goulet M, et al. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther. 2004;9(3):475–482
  28. Skuk D, Goulet M, Roy B, et al. Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol. 2006;65(4):371–386
  29. Skuk D, Goulet M, Roy B, et al. First test of a “high-density injection” protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord. 2007;17(1):38–46
  30. Calos MP. The phiC31 integrase system for gene therapy. Curr Gene Ther. 2006;6:633–645
  31. Minasi MG, Riminucci M, De Angelis L, et al. The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development. 2002;129(11):2773–2783
  32. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301–313
  33. Torrente Y, Belicchi M, Sampaolesi M, et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest. 2004;114(2):182–195
  34. Benchaouir R, Meregalli M, Farini A, et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell. 2007;1(6):646–657
  35. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447(7140):87–91
  36. Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA. 2000;97(12):6716–6721
  37. Lai Y, Yue Y, Liu M, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol. 2005;23(11):1435–1439
  38. Cormet-Boyaka E, Jablonsky M, Naren AP, Jackson PL, Muccio DD, Kirk KL. Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation. Proc Natl Acad Sci USA. 2004;101(21):8221–8226
  39. Lee S-J. Regulation of muscle mass by myostatin. Ann Rev Cell Dev Biol. 2004;20:61–86
  40. Klinge L, Aboumousa A, Eagle M, et al. New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry, in press. doi:10.1136/jnnp.2009.178038.
  41. Chiu YH, Hornsey MA, Klinge L, et al. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet. 2009;18(11):1976–1989
  42. Orkunoglu-Suer FE, Gordish-Dressman H, Clarkson PM, et al. INSIG2 gene polymorphism is associated with increased subcutaneous fat in women, poor response to resistance training in men. BMC Med Genet. 2008;9:117
  43. Yasunaga S, Grati M, Cohen-Salmon M, et al. A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness. Nat Genet. 1999;21(4):363–369
  44. Tekin M, Akcayoz D, Incesulu A. A novel missense mutation in a C2 domain of OTOF results in autosomal recessive auditory neuropathy. Am J Med Genet A. 2005;138(1):6–10
  45. Ramakrishnan NA, Drescher MJ, Drescher DG. Direct interaction of otoferlin with syntaxin 1A, SNAP-25, and the L-type voltage-gated calcium channel Cav1.3. J Biol Chem. 2009;284(3):1364–1372
  46. Drescher DG, Ramakrishnan NA, Drescher MJ. Surface plasmon resonance (SPR) analysis of binding interactions of proteins in inner-ear sensory epithelia. Methods Mol Biol. 2009;493:323–343
  47. Vandré DD, Ackerman WE, Kniss DA, et al. Dysferlin is expressed in human placenta but does not associate with caveolin. Biol Reprod. 2007;77(3):533–542
  48. Robinson JM, Ackerman WE, Behrendt NJ, Vandre DD. While dysferlin and myoferlin are coexpressed in the human placenta, only dysferlin expression is responsive to trophoblast fusion in model systems. Biol Reprod. 2009;81(1):33–39
  49. Lang CT, Markham KB, Behrendt NJ, et al. Placental dysferlin expression is reduced in severe preeclampsia. Placenta. 2009;30(8):711–718
  50. Linssen WH, de Visser M, Notermans NC, et al. Genetic heterogeneity in Miyoshi-type distal muscular dystrophy. Neuromuscul Disord. 1998;8(5):317–320
  51. Jarry J, Rioux MF, Bolduc V, et al. A novel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13–p12. Brain. 2007;130(2):368–380
  52. Jaiswal JK, Marlow G, Summerill G, et al. Defect in a novel membrane repair pathway in patients with a non-dysferlin Miyoshi myopathy. Traffic. 2007;8(1):77–88
  53. Tsutsumi S, Kamata N, Vokes TJ, et al. The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia (GDD). Am J Hum Genet. 2004;74:1255–1261
  54. Hartzell HC, Yu K, Xiao Q, Chien L-T, Qu Z. Anoctamin/TMEM16 family members are Ca2+-activated Cl− channels. J Physiol. 2009;587:2127–2139
  55. Pifferi S, Dibattista M, Menini A. TMEM16B induces chloride currents activated by calcium in mammalian cells. Pflugers Arch, in press. doi:10.1007/s00424-009-0684–9.
  56. Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest. 2008;118(5):1955–1964

PII: S0960-8966(09)00585-9

doi: 10.1016/j.nmd.2009.08.005

Neuromuscular Disorders
Volume 19, Issue 12 , Pages 867-873 , December 2009

Article Tools